Redwood AI's High-Wire Act: Board Resignation, Ebola MoU, and the Race to Deliver on Ambition

Canadian AI firm Redwood AI explores pathogen surveillance in Rwanda and post-quantum cybersecurity, but a board resignation and near-40% monthly stock drop highlight investor skepticism.

Redwood AI is betting on African pathogen surveillance and post-quantum cybersecurity to reshape its future, but a boardroom shake-up and a stock that has plunged almost 40% in a month tell a more sobering story. The Canadian artificial?intelligence firm, known mainly for AI-driven drug development and chemical analysis, now faces a credibility gap that even a double-digit share bounce has failed to close.

The turmoil reached the top on Friday when Graydon Bensler resigned from the board with immediate effect. No reason was given. The market’s response was swift: the stock hit a near?term low of CAD 2.90, extending a monthly slide of close to 40%. A technical rebound on Monday lifted shares by roughly 7% to CAD 3.10, but that still leaves the company miles from its April all?time high above CAD 10.

Amid the executive upheaval, Redwood AI is trying to turn the narrative toward new frontiers. The company signed a non?binding memorandum of understanding with the University of Global Health Equity in Rwanda to build a regional pathogen?tracking initiative. Led by Dr. Placide Sesonga, the project aims to monitor high?risk corridors near the border with the Democratic Republic of Congo. The software combines genome sequencing, geospatial data, and Redwood AI’s predictive platform to detect threats such as Ebola before they can spread.

Market observers are wary. The MoU carries no legal weight, and neither a budget nor committed funding has been disclosed. The company’s second?half 2026 agenda includes converting that letter into a binding contract and securing external capital, as well as integrating a planned acquisition of post?quantum cybersecurity firm QuantumIQ. Both steps are critical to reducing what analysts see as an over?reliance on the pharmaceutical segment.

On a more positive note, Redwood AI improved access for U.S. investors after the Depository Trust Company cleared its shares for electronic clearing on the OTCQB market. That news helped spark the recent recovery on Tradegate, where the stock climbed nearly 10% to EUR 1.98. The clearing approval eases trading friction that had amplified earlier losses.

The company is also making incremental progress in its core business. The Reactosphere chemistry database now holds 21 million chemical reactions, and in early June Redwood AI filed a U.S. patent application for a new planning module. These developments, however, are overshadowed by the broader volatility: the annualized volatility of the stock is currently above 130%, and the market capitalization stands at roughly CAD 116 million.

For Redwood AI, the gap between ambition and execution remains the central challenge. The Rwanda and QuantumIQ memorandums require firm, binding contracts to restore investor confidence. Until those materialize, the stock is likely to remain a high?volatility bet on promises rather than performance.